These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19636007)

  • 1. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.
    Laurent C; Do C; Gascoyne RD; Lamant L; Ysebaert L; Laurent G; Delsol G; Brousset P
    J Clin Oncol; 2009 Sep; 27(25):4211-6. PubMed ID: 19636007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
    Rudzki Z; Rucińska M; Jurczak W; Skotnicki AB; Maramorosz-Kurianowicz M; Mruk A; Piróg K; Utych G; Bodzioch P; Srebro-Stariczyk M; Włodarska I; Stachura J
    Pol J Pathol; 2005; 56(1):37-45. PubMed ID: 15921012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
    Momose S; Tamaru J; Kishi H; Mikata I; Mori M; Toyozumi Y; Itoyama S
    Hum Pathol; 2009 Jan; 40(1):75-82. PubMed ID: 18755494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
    Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma.
    Lai R; Medeiros LJ; Dabbagh L; Formenti KS; Coupland RW
    Mod Pathol; 2000 Mar; 13(3):223-8. PubMed ID: 10757332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
    Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
    Markovic O; Marisavljevic D; Cemerikic V; Perunicic M; Savic S; Filipovic B; Mihaljevic B
    Eur J Haematol; 2011 Mar; 86(3):246-55. PubMed ID: 21198858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
    Yi SH; Xu Y; Zou DH; An G; Zhao YZ; Qi JY; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):307-12. PubMed ID: 19799125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary colonic lymphoma: an analysis of 74 cases with localized large-cell lymphoma.
    Tang TC; Kuo MC; Chang H; Dunn P; Wang PN; Wu JH; Lin TL; Hung YS; Kuo TT; Shih LY
    Eur J Haematol; 2011 Jul; 87(1):28-36. PubMed ID: 21535155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL).
    Mencía-Gutiérrez E; Gutiérrez-Díaz E; Salamanca J; Martínez-González MA
    Int J Dermatol; 2006 Jun; 45(6):766-9. PubMed ID: 16796648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
    Chikatsu N; Kojima H; Suzukawa K; Shinagawa A; Nagasawa T; Ozawa H; Yamashita Y; Mori N
    Mod Pathol; 2003 Aug; 16(8):828-32. PubMed ID: 12920229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
    Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
    Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL.
    Suzuki Y; Yoshida T; Wang G; Togano T; Miyamoto S; Miyazaki K; Iwabuchi K; Nakayama M; Horie R; Niitsu N; Sato Y; Nakamura N
    Ann Hematol; 2012 Jul; 91(7):997-1005. PubMed ID: 22249209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Ninomiya S; Hara T; Tsurumi H; Hoshi M; Kanemura N; Goto N; Kasahara S; Shimizu M; Ito H; Saito K; Hirose Y; Yamada T; Takahashi T; Seishima M; Takami T; Moriwaki H
    Ann Hematol; 2011 Apr; 90(4):409-16. PubMed ID: 20938662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.
    Weisenburger DD; Anderson JR; Diebold J; Gascoyne RD; MacLennan KA; Müller-Hermelink HK; Nathwani BN; Ullrich F; Armitage JO
    Am J Hematol; 2001 Jul; 67(3):172-8. PubMed ID: 11391714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.